Anti-VHL, clone 11E12 (mouse monoclonal)

Species Reactivity	Key Applications	Host	Format	Antibody Type
M, H	WB, IP	M	Purified	Monoclonal Antibody

Species Reactivity

Key Applications

Host

Format

Antibody Type

M, H

WB, IP

Purified

Monoclonal Antibody

Description
Catalogue Number	MABC14
Description	Anti-VHL Antibody, clone 11E12
Alternate Names	von Hippel-Lindau disease tumor suppressor Protein G7 elongin binding protein von Hippel-Lindau syndrome pVHL
Background Information	von Hippel-Lindau protein (VHL) is most widely recognized as belonging to an E3 ubiquitin ligase complex that specifically targets hypoxia-inducible factors (HIFs) for the purpose of polyubiquitination and proteolytic degradation. Within this complex, VHL acts as a target recruitment subunit for HIFα and its subsequent ubiquitination. The complex also contains proteins such as B and C elongins, Rbx1 and Cul2. Inactivation of VHL has been linked to renal cell carcinoma development, therefore suggesting that VHL plays a role as a tumor suppressor. VHL expression has been observed in both fetal and adult kidney and brain tissues. Defects in VHL expression are causal to renal cell carcinoma type 1 (RCC1), erythrocytosis familial type 2 (ECYT2), von Hippel-Lindau disease (VHLD), and pheochromocytoma.

Description

Catalogue Number

MABC14

Description

Anti-VHL Antibody, clone 11E12

Alternate Names

von Hippel-Lindau disease tumor suppressor
Protein G7
elongin binding protein
von Hippel-Lindau syndrome
pVHL

Background Information

von Hippel-Lindau protein (VHL) is most widely recognized as belonging to an E3 ubiquitin ligase complex that specifically targets hypoxia-inducible factors (HIFs) for the purpose of polyubiquitination and proteolytic degradation. Within this complex, VHL acts as a target recruitment subunit for HIFα and its subsequent ubiquitination. The complex also contains proteins such as B and C elongins, Rbx1 and Cul2. Inactivation of VHL has been linked to renal cell carcinoma development, therefore suggesting that VHL plays a role as a tumor suppressor. VHL expression has been observed in both fetal and adult kidney and brain tissues. Defects in VHL expression are causal to renal cell carcinoma type 1 (RCC1), erythrocytosis familial type 2 (ECYT2), von Hippel-Lindau disease (VHLD), and pheochromocytoma.

Product Information
Format	Purified
Control	Mouse fetal brain tissue lysate
Presentation	Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Product Information

Format

Purified

Control

Mouse fetal brain tissue lysate

Presentation

Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Applications
Application	This Anti-VHL Antibody, clone 11E12 is validated for use in WB, IP for the detection of VHL.
Key Applications	Western Blotting Immunoprecipitation
Application Notes	Immunoprecipitation: It has been shown that this VHL clone will immunoprecipitate VHL from HEK 293 cells (Shoenfeld, 1998).

Applications

Application

This Anti-VHL Antibody, clone 11E12 is validated for use in WB, IP for the detection of VHL.

Key Applications

Western Blotting
Immunoprecipitation

Application Notes

Immunoprecipitation: It has been shown that this VHL clone will immunoprecipitate VHL from HEK 293 cells (Shoenfeld, 1998).

Biological Information
Immunogen	Purified human VHL
Clone	11E12
Concentration	Please refer to the Certificate of Analysis for the lot-specific concentration.
Host	Mouse
Isotype	IgG1κ
Species Reactivity	Mouse Human
Antibody Type	Monoclonal Antibody
Entrez Gene Number	NP_000542
Entrez Gene Summary	Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq].
Gene Symbol	VHL VHL1 HRCA1 RCA1 pVHL
Purification Method	Protein G
UniProt Number	P40337
UniProt Summary	FUNCTION: Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. PATHWAY: Protein modification; protein ubiquitination. SUBUNIT STRUCTURE: Component of the VCB (VHL-Elongin BC-CUL2) complex; this complex acts as a ubiquitin-ligase E3 and directs proteosome-dependent degradation of targeted proteins. Interacts with CUL2; this interaction is dependent on the integrity of the trimeric VBC complex. Interacts (via the beta domain) with HIF1A (via the NTAD domain); this interaction mediates degradation of HIF1A in normoxia and, in hypoxia, prevents ubiqitination and degradation of HIF1A by mediating hypoxia-induced translocation to the nucleus, a process which requires a hypoxia-dependent regulatory signal. Interacts with RNF139 and UBP33. Interacts with PHF17. SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane; Peripheral membrane protein. Nucleus. Note: Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated. Isoform 3: Cytoplasm. Nucleus. Note: Equally distributed between the nucleus and the cytoplasm but not membrane-associated. TISSUE SPECIFICITY: Expressed in the adult and fetal brain and kidney. DOMAIN: The Elongin BC complex binding domain is also known as BC-box with the consensus [APST]-L-x(3)-C-x(3)-[AILV]. INVOLVEMENT IN IDSEASE: Defects in VHL are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra-adrenal sympathetic ganglia and may be referred to as "paraganglioma." Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown. Defects in VHL are the cause of von Hippel-Lindau disease (VHLD) [MIM:193300]. VHLD is a dominantly inherited familial cancer syndrome characterized by the development of retinal angiomatosis, cerebellar and spinal hemangioblastoma, renal cell carcinoma (RCC), phaeochromocytoma and pancreatic tumors. VHL type 1 is without pheochromocytoma, type 2 is with pheochromocytoma. VHL type 2 is further subdivided into types 2A (pheochromocytoma, retinal angioma, and hemangioblastomas without renal cell carcinoma and pancreatic cyst) and 2B (pheochromocytoma, retinal angioma, and hemangioblastomas with renal cell carcinoma and pancreatic cyst). VHL type 2C refers to patients with isolated pheochromocytoma without hemangioblastoma or renal cell carcinoma. The estimated incidence is 3/100000 births per year and penetrance is 97% by age 60 years. Defects in VHL are the cause of erythrocytosis familial type 2 (ECYT2) [MIM:263400]; also called VHL-dependent polycythemia or Chuvash type polycythemia. ECYT2 is an autosomal recessive disorder characterized by an increase in serum red blood cell mass, hypersensitivity of erythroid progenitors to erythropoietin, increased erythropoietin serum levels, and normal oxygen affinity. Patients with ECYT2 carry a high risk for peripheral thrombosis and cerebrovascular events. Defects in VHL are a cause of renal cell carcinoma type 1 (RCC1) [MIM:144700]; also known as hypernephroma or adenocarcinoma of kidney. Familial renal cell carcinoma syndromes form a group of diseases characterized by a predisposition to development of renal cell carcinomas (RCCs) with various histological subtypes.
Molecular Weight	~ 24 kDa observed MW. VHL SUMOylation may result in high MW bands (Cai, 2010).

Biological Information

Immunogen

Purified human VHL

Clone

11E12

Concentration

Please refer to the Certificate of Analysis for the lot-specific concentration.

Host

Mouse

Isotype

IgG1κ

Species Reactivity

Mouse
Human

Antibody Type

Monoclonal Antibody

Entrez Gene Number

NP_000542

Entrez Gene Summary

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq].

Gene Symbol

VHL
VHL1
HRCA1
RCA1
pVHL

Purification Method

Protein G

UniProt Number

P40337

UniProt Summary

FUNCTION: Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases.

PATHWAY: Protein modification; protein ubiquitination.

SUBUNIT STRUCTURE: Component of the VCB (VHL-Elongin BC-CUL2) complex; this complex acts as a ubiquitin-ligase E3 and directs proteosome-dependent degradation of targeted proteins. Interacts with CUL2; this interaction is dependent on the integrity of the trimeric VBC complex. Interacts (via the beta domain) with HIF1A (via the NTAD domain); this interaction mediates degradation of HIF1A in normoxia and, in hypoxia, prevents ubiqitination and degradation of HIF1A by mediating hypoxia-induced translocation to the nucleus, a process which requires a hypoxia-dependent regulatory signal. Interacts with RNF139 and UBP33. Interacts with PHF17.

SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Membrane; Peripheral membrane protein. Nucleus. Note: Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated.

Isoform 3: Cytoplasm. Nucleus. Note: Equally distributed between the nucleus and the cytoplasm but not membrane-associated.

TISSUE SPECIFICITY: Expressed in the adult and fetal brain and kidney.

DOMAIN: The Elongin BC complex binding domain is also known as BC-box with the consensus [APST]-L-x(3)-C-x(3)-[AILV].

INVOLVEMENT IN IDSEASE: Defects in VHL are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra-adrenal sympathetic ganglia and may be referred to as "paraganglioma." Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown.

Defects in VHL are the cause of von Hippel-Lindau disease (VHLD) [MIM:193300]. VHLD is a dominantly inherited familial cancer syndrome characterized by the development of retinal angiomatosis, cerebellar and spinal hemangioblastoma, renal cell carcinoma (RCC), phaeochromocytoma and pancreatic tumors. VHL type 1 is without pheochromocytoma, type 2 is with pheochromocytoma. VHL type 2 is further subdivided into types 2A (pheochromocytoma, retinal angioma, and hemangioblastomas without renal cell carcinoma and pancreatic cyst) and 2B (pheochromocytoma, retinal angioma, and hemangioblastomas with renal cell carcinoma and pancreatic cyst). VHL type 2C refers to patients with isolated pheochromocytoma without hemangioblastoma or renal cell carcinoma. The estimated incidence is 3/100000 births per year and penetrance is 97% by age 60 years.

Defects in VHL are the cause of erythrocytosis familial type 2 (ECYT2) [MIM:263400]; also called VHL-dependent polycythemia or Chuvash type polycythemia. ECYT2 is an autosomal recessive disorder characterized by an increase in serum red blood cell mass, hypersensitivity of erythroid progenitors to erythropoietin, increased erythropoietin serum levels, and normal oxygen affinity. Patients with ECYT2 carry a high risk for peripheral thrombosis and cerebrovascular events.

Defects in VHL are a cause of renal cell carcinoma type 1 (RCC1) [MIM:144700]; also known as hypernephroma or adenocarcinoma of kidney. Familial renal cell carcinoma syndromes form a group of diseases characterized by a predisposition to development of renal cell carcinomas (RCCs) with various histological subtypes.

Molecular Weight

~ 24 kDa observed MW. VHL SUMOylation may result in high MW bands (Cai, 2010).

Product Usage Statements
Quality Assurance	Evaluated by Western Blot in mouse fetal brain tissue lysate. Western Blot Analysis: 1 µg/mL of the antibody detected VHL in 10 µg of mouse fetal brain tissue lysate.
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Product Usage Statements

Quality Assurance

Evaluated by Western Blot in mouse fetal brain tissue lysate.

Western Blot Analysis: 1 µg/mL of the antibody detected VHL in 10 µg of mouse fetal brain tissue lysate.

Usage Statement

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	Stable for 1 year at 2-8°C from date of receipt.

Storage and Shipping Information

Storage Conditions

Stable for 1 year at 2-8°C from date of receipt.

Packaging Information
Material Size	100 µg

Packaging Information

Material Size

100 µg

实验耗材

分子生物学试剂

蛋白与免疫学

生化试剂

细胞及检测试剂

色谱及层析

仪器设备

实验服务

办公用品

Anti-VHL, clone 11E12 (mouse monoclonal)

浏览了该商品的用户最终购买

浏览了该商品的用户还浏览了

特卖

重要规格表

我要咨询